ClinConnect ClinConnect Logo
Search / Trial NCT06419608

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

Launched by BIOHAVEN THERAPEUTICS LTD. · May 14, 2024

Trial Information

Current as of June 27, 2025

Recruiting

Keywords

Depression Depressed Depressive Disorder Major Depression Major Depressive Episode Antidepressant

ClinConnect Summary

This clinical trial is studying a new treatment called BHV-7000 for people with Major Depressive Disorder (MDD). The goal is to see how well this treatment works and how safe it is for individuals experiencing moderate to severe depression. The study is currently looking for participants aged 18 to 75 who have been feeling depressed for at least two months and are willing to stop taking other medications for depression before joining the trial.

If you or someone you know is struggling with depression and meets the eligibility criteria, this trial could be an option. Participants will receive the treatment and will be closely monitored by the research team throughout the study. It's important to note that individuals with certain medical histories or currently taking multiple depression medications may not qualify. Overall, this trial aims to explore a new option for those who need help managing their depression.

Gender

ALL

Eligibility criteria

  • Key Inclusion Criteria:
  • 1. Subjects experiencing a moderate to severe episode of depression.
  • 2. Subjects experiencing a current episode of depression for at least 2 months.
  • 3. Subjects must be willing to discontinue all psychotropic medications (other medications to treat depression) before entering the study.
  • 4. Male and Female participants 18 to 75 years of age at the time of consent.
  • 5. Body Mass Index (BMI) must be ≥ 18 kg/m2 and ≤ 35 kg/m2.
  • Key Exclusion Criteria:
  • 1. Subjects taking more than 2 medications (other than benzodiazepines and medications targeting insomnia) to treat depression at the screening visit.
  • 2. Subjects with a history of bipolar disorder, schizophrenia, or other neuropsychiatric conditions that may interfere with the conduct of the study.
  • 3. Subjects with a history of medical conditions that may interfere with the conduct of the study.
  • 4. Females who are pregnant, breastfeeding or planning to become pregnant.

About Biohaven Therapeutics Ltd.

Biohaven Therapeutics Ltd. is a biopharmaceutical company focused on developing innovative treatments for neurological and psychiatric disorders. With a commitment to addressing unmet medical needs, Biohaven leverages cutting-edge science and advanced drug development methodologies to create transformative therapies. The company's pipeline includes novel compounds aimed at improving the lives of patients suffering from conditions such as migraine, depression, and neurodegenerative diseases. Through rigorous clinical trials and a dedication to research excellence, Biohaven strives to deliver impactful solutions that enhance patient care and drive advancements in the field of medicine.

Locations

New York, New York, United States

Redlands, California, United States

Media, Pennsylvania, United States

Toms River, New Jersey, United States

Rochester, New York, United States

Allentown, Pennsylvania, United States

Cedarhurst, New York, United States

Stanford, California, United States

Cherry Hill, New Jersey, United States

Dayton, Ohio, United States

Desoto, Texas, United States

New York, New York, United States

Flowood, Mississippi, United States

Chicago, Illinois, United States

Bellevue, Washington, United States

Oceanside, California, United States

Brooklyn, New York, United States

Boston, Massachusetts, United States

Colorado Springs, Colorado, United States

Orlando, Florida, United States

Mount Kisco, New York, United States

Jacksonville, Florida, United States

Orange, California, United States

Plano, Texas, United States

Farmington, Connecticut, United States

Wichita Falls, Texas, United States

New Orleans, Louisiana, United States

Anaheim, California, United States

Gaithersburg, Maryland, United States

North Charleston, South Carolina, United States

Watertown, Massachusetts, United States

Upland, California, United States

Boston, Massachusetts, United States

Dallas, Texas, United States

San Jose, California, United States

West Palm Beach, Florida, United States

Encino, California, United States

Naples, Florida, United States

Overland Park, Kansas, United States

Decatur, Georgia, United States

Savannah, Georgia, United States

Garden Grove, California, United States

New York, New York, United States

Saint Louis, Missouri, United States

Portland, Oregon, United States

Elgin, Illinois, United States

Rogers, Arkansas, United States

Phoenix, Arizona, United States

Las Vegas, Nevada, United States

Chandler, Arizona, United States

Little Rock, Arkansas, United States

Bellflower, California, United States

Garden Grove, California, United States

Los Angeles, California, United States

Riverside, California, United States

Miami Lakes, Florida, United States

Tampa, Florida, United States

Staten Island, New York, United States

Moosic, Pennsylvania, United States

Austin, Texas, United States

Dallas, Texas, United States

Houston, Texas, United States

Clinton, Utah, United States

Torrance, California, United States

Baltimore, Maryland, United States

Norwich, Connecticut, United States

Walnut Creek, California, United States

Little Rock, Arkansas, United States

Chino, California, United States

Farmington, Connecticut, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported